Tue. 27 Feb 2024, 6:03am ET
Benzinga
Earnings, News
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.48) by 4.17 percent. This is a 34.21 percent increase over losses of $(0.76) per share from the same period last year. The company reported quarterly sales of $32.25 million which beat the analyst consensus estimate of $28.70 million by 12.37 percent. This is a 71.38 percent increase over sales of $18.82 million the same period last year.